News

UTSW researchers identify novel mechanism in innate immunity signaling

UTSW researchers identify novel mechanism in innate immunity signaling

 

Work from Dr. James Chen's lab published in Science demonstrates that cGAS binds with DNA to form droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body’s first response to infection. Press release

UTSW recognized as a VHL Clinical Care Center

UTSW recognized as a VHL Clinical Care Center

 

The VHL Alliance recognizes UT Southwestern as a VHL Clinical Care Center, one of 21 in the US, and the only one in North Texas. VHL, or von Hippel-Lindau disease, is a genetic/familial condition characterized by mutation in the VHL gene and a predisposition to kidney cancer. These centers are committed to providing outstanding holistic, coordinated care for VHL patients.

KCP researchers leverage extensive RCC tumorgraft platform to understand the tumor microenvironment

KCP researchers leverage extensive RCC tumorgraft platform to understand the tumor microenvironment

 

Drs. Wang and Brugarolas report an empirical approach using tumorgraft models and a computational program called DisHet to dissect the tumor microenvironment. Press Release  

SPORE Career Development Awardee, Dr. Banaszynski, is awarded a Kidney Cancer Research Program Early-Career Investigator Award

SPORE Career Development Awardee, Dr. Banaszynski, is awarded a Kidney Cancer Research Program Early-Career Investigator Award

 

Dr. Laura Banaszynski was selected as one of the funding recipients of the first national Kidney Cancer Research Program awards. The title of her application is "Chromatin Dysregulation and Metabolism Disorder in Kidney Cancer".

Drs. Margulis and Wait lead consortium to refine markers of prognosis in invasive kidney cancer

Drs. Margulis and Wait lead consortium to refine markers of prognosis in invasive kidney cancer

 

Dr. Vitaly Margulis, Associate Professor of Urology, and Dr. Michael Wait, Professor of Cardiovascular and Thoracic Surgery, lead a research team of top-tier investigators from Mayo Clinic, MD Anderson Cancer Center, Emory University, Indiana University, and the University of Wisconsin to help identify factors that can affect kidney cancer recurrence following surgery. Manuscript  Press Release

Dr. DeBerardinis named Howard Hughes Medical Institute investigator

Dr. DeBerardinis named Howard Hughes Medical Institute investigator

 

Dr. Ralph DeBerardinis, Professor at the Children’s Medical Center Research Institute at UT Southwestern (CRI), becomes UT Southwestern's latest Howard Hughes Medical Institute (HHMI) Investigator, bringing the total number of HHMI investigators to 15. Dr. DeBerardinis is Chief of the Division of Pediatric Genetics and Metabolism at UT Southwestern and an attending physician at Children’s Health. He is also a Professor of Pediatrics and member of the Eugene McDermott Center for Human Growth and Development. Dr. DeBerardinis serves as a KCP Co-Leader, Metabolism, and is a kidney SPORE project leader. Press Release

KCP urological surgeon, Dr. Vitaly Margulis, discusses groundbreaking SABR trial at AUA

KCP urological surgeon, Dr. Vitaly Margulis, discusses groundbreaking SABR trial at AUA

 

Dr. Margulis presents data on a groundbreaking clinical trial incorporating stereotactic radiation for the management of kidney cancer tumor thrombi prior to surgery at the Plenary Session of the American Urological Association Annual Meeting held in San Francisco on May 18, 2018.

FDA approves combination immunotherapy treatment for metastatic kidney cancer

FDA approves combination immunotherapy treatment for metastatic kidney cancer

 

The Food and Drug Administration grants approval for the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. The approval comes following the findings of the CheckMate-214 study, which was sponsored by Bristol-Myers Squibb and co-led by Dr. Hans Hammers. Press Release

Dr. Hannan and colleagues report on efficacy of immune checkpoint inhibition combined with SBRT

Dr. Hannan and colleagues report on efficacy of immune checkpoint inhibition combined with SBRT

 

Dr. Raquibul Hannan and colleagues report results from one of the largest series of cancer patients (mostly kidney and melanoma) treated with immune checkpoint inhibitors together with modern hypofractionated radiation, such as stereotactic body radiation therapy (SBRT). Abstract

Former kidney donor joins KCP staff as first Director of Patient Experience at UT Southwestern

Former kidney donor joins KCP staff as first Director of Patient Experience at UT Southwestern

 

The KCP welcomes Megan Dougherty, R.N., as Director of Patient Experience. Ms. Dougherty will be the first Director of Patient Experience at UT Southwestern.